No Alarm At Almirall Despite Stake Sale
Pipeline Progressing Well
Shares in the Spanish dermatology specialist have slipped as the majority shareholder sold a 6.3% stake. However, sales of its psoriasis and acne drugs, plus some promising late-stage assets, suggest Almirall is in rude health.
You may also be interested in...
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.